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Introduction
Prostate cancer is the most commonly diagnosed cancer in western countries and represents a significant healthcare burden in Canada; 1 in 6 men will be diagnosed with the disease in their lifetime. 1, 2 Despite its prevalence and associated morbidity and mortality, early detection remains controversial, most recently due to conflicting messages from 2 pivotal randomized trials 3, 4 and because of the potential for over-diagnosis and overtreatment of men with indolent prostate cancer. 3 Many national organizations and advocacy groups, including the Canadian Urological Association (CUA), have published guidelines regarding prostate-specific antigen (PSA) testing. 5, 6 They explain that the presence of prostate cancer is not indicated by a single PSA cutoff point but, instead, that a higher PSA level is associated with a higher risk of disease. 7 Therefore, these guidelines stress the importance of shared decision-making between the patient and his doctor. 6, 7 Because of the ambiguity of this recommendation, there is significant variation in screening practice across multiple factors that are not clinically relevant, such as geographic location, remuneration mechanism, and personal opinion. [7] [8] [9] [10] [11] Ultimately, any realized benefit of PSA screening, as well as potential harm, will rest on the decision to perform a transrectal ultrasound and biopsy (TRUS-BX). However, uncertainty about PSA result interpretation leads to uncertainty about when to biopsy. 6, 7 Although it would appear that, in Canada, the main driver of TRUS-BX is patient age relative to total PSA values, 11 other factors add to the clinical complexity and these need to be considered in the decision to biopsy. These factors include: PSA levels relative to prostate volume, PSA kinetics, family history, ethnicity, and comorbidities. 6 The situation has recently been amplified by findings such as those from the prostate cancer prevention trial (PCPT), 12 indicating that historical cutoff levels for prostate cancer screening using a PSA level of 4 ng/mL may no longer be appropriate, particularly among younger men. Lastly, the decision to biopsy needs to be weighed against the complication rates of TRUS-BX, [13] [14] [15] [16] [17] [18] [19] particularly with more recent understanding of the frequency of serious infectious complications requiring hospitalization.
Given the controversy around optimal screening and diagnosis of early prostate cancer, as well as the ambivalent recommendations from national and international bodies, we expected that, in this post-screening trial era, there would be important differences among urologists about who is offered biopsy which could lead to significant differences in quality of prostate cancer care. Our aim was to document current biopsy recommendations based on different clinical scenarios.
Methods
We surveyed all active Ontario members of the CUA for their views on when to biopsy the prostate. Our mailed survey was designed to capture biopsy preferences in ambiguous clinical situations using a 5-point Likert scale anchored at "recommend against biopsy" and "recommend for biopsy." The questions encompassed 10 scenarios that varied regarding factors that could affect the urologist's decision (Table  1) . We consulted multiple practice guidelines to relate our scenarios to standard practice regarding investigation recommendations and we used those guidelines along with clinical experience (RS) to state explicit choices for or against biopsy for each scenario (Table 1) . 5, 6, [20] [21] [22] [23] [24] We also collected 7 descriptors of the urology participants that might have been associated with their biopsy practice: age, sex, number of years since graduation, whether they do prostate biopsies and/or prostatectomies, hospital type, and location. The full survey is provided in Appendix 1.
We used a modified Dillman method to maximize survey response. Specifically, we sent a second mailing 1 month after the initial mailing to all who had not yet completed the questionnaire. 25 We stopped accepting responses 1 month after the second mailing. The initial questionnaire package included a pre-addressed, pre-stamped return envelope and a $5 gift certificate. Data were anonymized using a unique questionnaire identification number and were recorded in a Microsoft Office Access 2007 database.
We presented the Likert-scale distributions for each scenario and indicated which response agreed with the study 
Results
Of the original 148 questionnaires sent, 108 eligible responses were received and 2 had moved out of the province for an overall response rate of 74.0%. Of those responses, 101 answered all of the 10 clinical scenarios (Table 2 ). In total, 57% of respondents were in community hospitals, 24% performed more than 140 biopsies per year and more than 30 prostatectomies. Over 52% reported performing no biopsies, likely due to biopsy referrals made to radiology or other urology colleagues.
We illustrated the distribution of Likert responses for each of the 10 clinical scenarios (Fig. 1) . We highlighted the responses that agree with our guideline-based assignment about whether a biopsy was warranted by taking a response of 1 or 2 as representing recommendation against biopsy and a response of 4 or 5 as representing recommendation for biopsy. Most concurred with this assignment, but the degree of concurrence varied from a low of 42% for scenario 4 to a high of 89% for scenario 9. Over 80% concurred with our assignment against biopsy for scenarios 2, 3, and 9 and with our assignment for biopsy in scenario 5. Agreement with our assignment exceeded 70% in scenarios 8 and 10.
The average summed biopsy score across all 10 scenarios was 27.9 (standard deviation 5.6, range: 17-40) out of a possible total score of 50. None of the urologist descriptors were associated with the average biopsy scores except for the average annual number of biopsies performed, which showed an increase of 3.4 in the propensity to biopsy score across the 3 categories (p = 0.04) ( Table 3) .
Discussion
Active members of the CUA from Ontario were sent a questionnaire about their opinion to recommend for or against biopsy in 10 hypothetical cases. We achieved a response rate of 74%, which is high for such surveys. We take this as an indication of the level of interest in this topic. With this response, we interpret our results as providing a population-based view of the variations in opinion about when to conduct a prostate biopsy in ambiguous clinical situations. Perhaps not surprisingly, urologists who conduct a lot of biopsies had a higher propensity to biopsy such cases.
While most respondents agreed with our guidelineinformed study assignments to recommend for or against biopsy, there was a sizeable number who did not. This lack of consensus could be largely due to the variations in guidance that is being provided by the various standard setting bodies 5, 6, 20, 21, 24 and the challenge of choosing and/ or using such guidance in everyday clinical practice. Our stated biopsy recommendations were explicit; we asked respondents if they were in favour of or against biopsy in an attempt to come to an actual decision, regardless of the ambiguity of the case (Table 1) , representing informed, albeit arbitrary, decisions. It is interesting to note that in this study, the clinical drivers in those scenarios with the greatest concordance were age, suspicious digital rectal examination and a low PSA value (particularly a PSA between 2.0 and 3.0). This pattern is observed despite the well-described incidence of prostate cancer (nearly 24%) in the PCPT trial for PSA values in this range.
12 Ethnicity (scenario 8) influenced respondent's biopsy recommendations toward favouring biopsy; obesity, on the other hand, a putative risk factor for prostate cancer, did not strongly influence the recommendations in the presence of the competing concern of life expectancy/comorbidities (scenario 10) -most respondents recommended against biopsy. The greatest discordance with the study team's designated standard recommendation was for scenario 4 at 42% exploring the role of free PSA in the decision to biopsy.
Urologists' clinical decisions may be influenced by previous personal or anecdotal experience in addition to guidelines, especially in the presence of inconclusive advice. In the United Kingdom, Burden and colleagues surveyed 733 conference attendee urologists on their usage of guidelines about the usage of PSA tests and subsequent biopsy investigations. In that study, of the 47% who responded, there was a wide variation of their use of guidelines and 42% were not aware of the current PSA cut-off recommendations. 26 Similarly, Lawrentschuk and colleagues conducted a survey of CUA members to document what PSA levels lead to a recommendation for ultrasound guided biopsy and to explore if there were other factors that influenced further investigations. Of the 360 urologists surveyed, the 35% who responded indicated a considerable amount of variation with each of their scenarios. Their use of a factorial design identified age and PSA as influential to practice. 11 Our study adds to this work in that it explored urologists' viewpoints about more ambiguous, multifactorial cases. Also, our results reflect urologists' preferences after the release of the Prostate, Lung, Colorectal, and Ovarian (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSPC) screening study findings.
Our results are restricted to Ontario urologists who were active members of the CUA because of limited time, funding, and mailing list availability. Active CUA members, who make up about 75% of all active Ontario urologists, may be more likely to follow guidelines thereby increasing our findings on guideline concordance. Restriction to Ontario may have reduced the amount of practice variation we observed compared to what the results of a Canada-wide survey might have revealed. Our results do not reflect the views of the 26% who did not respond. We were unable to compare characteristics of non-respondents to provide information about the representativeness of our study population. We did not use a factorial design, which would have involved Variations in prostate biopsy practice many more than 10 scenarios, to isolate the various patient factors that might have influenced biopsy assignments and we minimized questions about respondent's training. These were deliberate decisions made to maximize our response rate by keeping the questionnaire short.
Conclusion
We collected information about prostate biopsy clinical decision-making from a large sample of urologists from across Ontario. We documented that this decision-making varies and we speculated that this variation is due to a lack of clear practice guidance in this area. Further studies should try and determine the specific aspects of a clinical case that may underlie these variations and specifically probe the rationale for decision-making. This information could inform professional organizations and advocacy groups developing guidelines or recommendations regarding the relative appropriateness of prostate biopsy.
